• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

IRA's in­fla­tion-linked re­bates would've saved gov­ern­ment $3.7B from 2018 to 2020 — JA­MA re­search

3 years ago
Pharma

Can­cer care brand­ing: Will City of Hope and Can­cer Treat­ment Cen­ters of Amer­i­ca brands work ‘bet­ter to­geth­er’?

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er rolls out Covid boost­er so­cial ads with in­flu­encers; Ab­b­Vie re­tires Hu­mi­ra TV

3 years ago
Marketing

Jasper Ther­a­peu­tics sees a stock boost af­ter sick­le cell da­ta re­lease; Newron lifts the veil on da­ta for ...

3 years ago
News Briefing

Fi­bro­sis start­up touts mid-stage NASH tri­al as it moves sole can­di­date for­ward

3 years ago
R&D

Af­ter dis­as­trous Gala­pa­gos deal, Gilead finds new rheuma­toid arthri­tis part­ner

3 years ago
Startups
Deals

Every drug ap­proved in 2022: A year of few­er new prod­ucts, but gene ther­a­py firsts and new block­busters

3 years ago
R&D
Special

Scoop: Bing Yao’s Ar­riVent lin­ing up $145M raise, af­ter $150M de­but in 2021

3 years ago
Financing
Startups

Con­gres­sion­al in­quiry in­to 'high­ly atyp­i­cal' FDA-Bio­gen ties ends with damn­ing re­port, no reper­cus­sions

3 years ago
Pharma
FDA+

Up­dat­ed: Off-the-shelf cell ther­a­py pi­o­neer Al­lo­gene re­cruits a Kite vet to run R&D

3 years ago
Bioregnum
R&D

Forge spin­off Black­smith Med­i­cines merges back in­to com­pa­ny two years af­ter launch, but de­tails are slim

3 years ago
Deals

Scoop: J&J-backed Aro Bio­ther­a­peu­tics eyes nine-fig­ure raise with first tri­al on hori­zon

3 years ago
Financing
Startups

Tiny IPO clos­es out Nas­daq's bar­ren biotech year

3 years ago
Financing

Ex­clu­sive: In lieu of an IPO in rocky biotech mar­ket, Ap­n­imed lines up $80M from ex­ist­ing in­vestors for two PhI­II ...

3 years ago
Financing
Startups

TG cross­es the fin­ish line in MS, turn­ing U2 com­po­nent in­to stand­alone drug for biotech's sec­ond ap­proval

3 years ago
FDA+

Up­dat­ed: US puts hold on F-star's takeover by Chi­na’s Sino Bio­pharm, cit­ing na­tion­al se­cu­ri­ty risks

3 years ago
Deals
China

News wrap: Equi­l­li­um ax­es Metacrine merg­er; Two phar­mas pen ADC deals

3 years ago
News Briefing

FDA grants ap­peal for Arde­lyx chron­ic kid­ney dis­ease drug af­ter Ju­ly 2021 re­jec­tion

3 years ago
R&D
FDA+

Pfiz­er re­leas­es he­mo­phil­ia B PhI­II da­ta in chal­lenge to CSL's Hem­genix

3 years ago
R&D

Scoop: To fund Covid-19 nasal vac­cine boost­er, Yale spin­out snags Se­ries A

3 years ago
Financing
Startups

Ever­est Med­i­cines be­gins pro­duc­tion at its new $129M+ mR­NA vac­cine man­u­fac­tur­ing fa­cil­i­ty in Chi­na

3 years ago
Coronavirus
Manufacturing

With fo­cus on ne­glect­ed eye dis­eases, Opus buys two gene ther­a­pies from Iver­ic Bio

3 years ago
Startups
Deals

Gilead buys out cash-hun­gry part­ner Jounce's an­ti­body for $67M

3 years ago
Deals

FDA is­sues warn­ing let­ter to South Amer­i­can in­gre­di­ent man­u­fac­tur­er over da­ta prob­lems

3 years ago
FDA+
Manufacturing
First page Previous page 397398399400401402403 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.